Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma
Abstract Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lymphoma cells (CL) at diagnosis. Previous studies were limited by small sample size precluding robust analysis. Hence, we evaluated the prognostic relevance of CL cells in ne...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-024-01658-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544386963308544 |
|---|---|
| author | Sayan Mullick Chowdhury Subodh Bhatta Timothy J. Voorhees Kaitlin Annunzio David A. Bond Yazeed Sawalha Audrey Sigmund Walter Hanel Lalit Sehgal Lapo Alinari Robert Baiocchi Kami Maddocks Beth Christian Dan Jones Narendranath Epperla |
| author_facet | Sayan Mullick Chowdhury Subodh Bhatta Timothy J. Voorhees Kaitlin Annunzio David A. Bond Yazeed Sawalha Audrey Sigmund Walter Hanel Lalit Sehgal Lapo Alinari Robert Baiocchi Kami Maddocks Beth Christian Dan Jones Narendranath Epperla |
| author_sort | Sayan Mullick Chowdhury |
| collection | DOAJ |
| description | Abstract Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lymphoma cells (CL) at diagnosis. Previous studies were limited by small sample size precluding robust analysis. Hence, we evaluated the prognostic relevance of CL cells in newly diagnosed DLBCL patients. Based on peripheral blood (PB) immunophenotyping, patients were grouped into CL + and CL−. CL was defined as detectable clonally restricted B-cells that matched the actual or expected B-cell immunophenotype of DLBCL. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS) and diagnosis-to-treatment interval (DTI). Among the 1266 patients with DLBCL, 621 had PB flow at diagnosis, and after excluding patients not meeting eligibility criteria, 588 cases remained. Among these, 85 (15%) were CL + and 503 were CL- (85%). Patients in CL + group were younger (67 vs. 70 years, p = 0.03) with a higher proportion of non-bulky disease (85% vs. 56%, p < 0.0001), normal albumin (79% vs. 54%, p < 0.0001), and MYC/BCL2 and/or BCL6 rearrangements (18% vs. 7%, p = 0.003) compared to the CL − group. Patients with CL at diagnosis had significantly inferior PFS and OS compared with those without CL. After adjusting for factors associated with inferior PFS and OS in univariable analysis, presence of CL remained significantly associated with inferior PFS (HR = 2.04, 95%CI = 1.47–2.84, p < 0.0001) and OS (HR = 1.61, 95%CI = 1.1–2.36, p = 0.01), respectively. There was no significant difference in DTI between the two groups. Given the prognostic relevance associated with presence of CL, clinicians should consider checking PB flow at diagnosis in all newly diagnosed DLBCL patients. |
| format | Article |
| id | doaj-art-c6a6ce24fc0b46b39d2dbc9636fd364f |
| institution | Kabale University |
| issn | 1756-8722 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj-art-c6a6ce24fc0b46b39d2dbc9636fd364f2025-01-12T12:36:36ZengBMCJournal of Hematology & Oncology1756-87222025-01-011811410.1186/s13045-024-01658-yImpact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphomaSayan Mullick Chowdhury0Subodh Bhatta1Timothy J. Voorhees2Kaitlin Annunzio3David A. Bond4Yazeed Sawalha5Audrey Sigmund6Walter Hanel7Lalit Sehgal8Lapo Alinari9Robert Baiocchi10Kami Maddocks11Beth Christian12Dan Jones13Narendranath Epperla14Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityDepartment of Pathology, The Ohio State UniversityDivision of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State UniversityAbstract Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lymphoma cells (CL) at diagnosis. Previous studies were limited by small sample size precluding robust analysis. Hence, we evaluated the prognostic relevance of CL cells in newly diagnosed DLBCL patients. Based on peripheral blood (PB) immunophenotyping, patients were grouped into CL + and CL−. CL was defined as detectable clonally restricted B-cells that matched the actual or expected B-cell immunophenotype of DLBCL. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS) and diagnosis-to-treatment interval (DTI). Among the 1266 patients with DLBCL, 621 had PB flow at diagnosis, and after excluding patients not meeting eligibility criteria, 588 cases remained. Among these, 85 (15%) were CL + and 503 were CL- (85%). Patients in CL + group were younger (67 vs. 70 years, p = 0.03) with a higher proportion of non-bulky disease (85% vs. 56%, p < 0.0001), normal albumin (79% vs. 54%, p < 0.0001), and MYC/BCL2 and/or BCL6 rearrangements (18% vs. 7%, p = 0.003) compared to the CL − group. Patients with CL at diagnosis had significantly inferior PFS and OS compared with those without CL. After adjusting for factors associated with inferior PFS and OS in univariable analysis, presence of CL remained significantly associated with inferior PFS (HR = 2.04, 95%CI = 1.47–2.84, p < 0.0001) and OS (HR = 1.61, 95%CI = 1.1–2.36, p = 0.01), respectively. There was no significant difference in DTI between the two groups. Given the prognostic relevance associated with presence of CL, clinicians should consider checking PB flow at diagnosis in all newly diagnosed DLBCL patients.https://doi.org/10.1186/s13045-024-01658-yDiffuse large B-cell lymphomaDLBCLCirculating lymphoma cellsCLPrognosisProgression-free survival |
| spellingShingle | Sayan Mullick Chowdhury Subodh Bhatta Timothy J. Voorhees Kaitlin Annunzio David A. Bond Yazeed Sawalha Audrey Sigmund Walter Hanel Lalit Sehgal Lapo Alinari Robert Baiocchi Kami Maddocks Beth Christian Dan Jones Narendranath Epperla Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma Journal of Hematology & Oncology Diffuse large B-cell lymphoma DLBCL Circulating lymphoma cells CL Prognosis Progression-free survival |
| title | Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma |
| title_full | Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma |
| title_fullStr | Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma |
| title_full_unstemmed | Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma |
| title_short | Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma |
| title_sort | impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large b cell lymphoma |
| topic | Diffuse large B-cell lymphoma DLBCL Circulating lymphoma cells CL Prognosis Progression-free survival |
| url | https://doi.org/10.1186/s13045-024-01658-y |
| work_keys_str_mv | AT sayanmullickchowdhury impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT subodhbhatta impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT timothyjvoorhees impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT kaitlinannunzio impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT davidabond impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT yazeedsawalha impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT audreysigmund impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT walterhanel impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT lalitsehgal impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT lapoalinari impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT robertbaiocchi impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT kamimaddocks impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT bethchristian impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT danjones impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma AT narendranathepperla impactofcirculatinglymphomacellsatdiagnosisonoutcomesinpatientswithnewlydiagnoseddenovodiffuselargebcelllymphoma |